Bob Evans Farms, Inc. Message Board
-
Very little volume before the release. Everyone waiting on the sidelines??
-
I believe the report comes out after the bell today from a press release earlier. I have the same expecations!!
-
Well next week we will all know. With them in the quiet period till earnings anticipation is running high!! Will the be the report of the Smart Sponge leaving the train station!! Good luck to all longs.
- Reply to
WE ARE NOW IN WALGREENS !!!! THIS IS HUGE NEWS !!!! BUY
by winston10024 •May 9, 2013 11:06 AMsweet. LEt's see this thing jump now!!!
-
it is interesting. Holding it down.
-
agree. News could be close .
-
Nice to see some volume today. Now give us a contract to se the volume soar!!!
-
so quiet. We sure need some news!! Trading is pathetic.
-
Good stuff
- Reply to
Daymond John responds to The Street article on Twitter
by steveluker43 •Apr 17, 2013 12:32 AMNice. You don't want to mess with Daymond!!!
Thanks for posting his tweat. -
I sure hope so.
-
You are correct. They seem to stress that on the Galaxy release.
-
no doubt
-
The price and volume went nuts. What was the CEO on?
- Reply to
John Daymond on Mad Money tonight, if he mentions DROP watch out!
by tradingjunk123 •Apr 11, 2013 9:58 AMagree perfect timing.
Nice green start for DROP today. They couldn't have planned it any better with TIger game back and probably the most watched event for golf. -
Let all see that FUSE golf bag!!!
-
IT would be great to get some news on a Friday. They were doing that quite regularly.
-
Give it to them Dr. Berger!!! I think they made him mad tossing out these lies about his drug.
-
Here is the scoop as I can't link
Zalicus Granted Key Formulation Patent for Z160
Extends Z160 Patent Coverage through March 2032
Business WirePress Release: Zalicus Inc. – 11 minutes agoEmail0Share0PrintRELATED QUOTESSymbol Price Change
ZLCS 0.6599
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled “Solid Dispersion Formulations and Methods of Use Thereof,” provides broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain.
“We are delighted to have been issued this important patent extending Z160’s patent protection and exclusivity into 2032,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Solid dispersion technology is well-characterized and has been utilized in a number of commercial and late-stage development products. Building on this knowledge, Zalicus has developed solid dispersion formulations of Z160 that have uniquely improved its bioavailability and have facilitated its advancement into two ongoing Phase 2a clinical trials in chronic neuropathic pain.”
About Z160
Zalicus is currently advancing Z160, a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker, through Phase 2a clinical development in chronic neuropathic pain. Z160 is designed to selectively target neuronal pain signaling by modulating neurons that are undergoing high-frequency firing. Z160 has demonstrated efficacy in multiple animal models of neuropathic and inflammatory pain, suggesting that it has the potential to treat a broad range of chronic pain conditions. Additionally, clinical trials in over 200 subjects have es